Embecta Shares Gain As Q1 Earnings Exceed Expectations

Embecta Corp (NASDAQ:EMBC) posted Q1 FY23 revenues of $275.7 million, down 4.7% on a reported basis and up 0.7% on…
  • Embecta Corp (NASDAQ:EMBC) posted Q1 FY23 revenues of $275.7 million, down 4.7% on a reported basis and up 0.7% on a constant currency basis, beating the consensus of $262.90 million.
  • Lower revenues were driven by unfavorable effects from foreign currency translation primarily due to the strengthening of the U.S. dollar.
  • The company posted an adjusted EPS of $0.96, beating the consensus of $0.51.
  • U.S. revenues decreased by 1.1% on both a reported and constant currency basis.
  • International revenues decreased 8.7% on a reported basis and increased 2.6% on a constant currency basis.
  • The company posted adjusted gross profit and margin of $188.9 million and 68.5%, respectively.
  • Operating income and margin of $88.8 million and 32.2%, compared to $116.6 million and 40.3% in the prior year period.
  • Outlook: Embecta has raised its FY23 guidance with revenues of $1.084-$1.107 billion, up from $1.05-$1.073 billion vs. an estimate of $1.06 billion.
  • It forecasts adjusted EPS of $2.20-$2.35 versus the prior guidance of $1.75 – $2.00 and the consensus of $1.90.
  • Price Action: EMBC shares are up 9.13% at $31.02 on the last check Tuesday.
Total
0
Shares
Related Posts
Read More

IBio Divesting CDMO Business and CGMP Biologics Manufacturing Facility, to Result in About 50% Annualized Cost Savings; Commenced Workforce Reduction of Approximately 60% of Current Company Staffing Levels

iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company") an AI-driven innovator of precision antibody immunotherapies, announces it is seeking to divest its contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its transformation into an antibody discovery and development company.

IBIO